TNF Inhibitors - A Pipeline Analysis Report

TNF Inhibitors - A Pipeline Analysis Report

  • October 2017 •
  • 70 pages •
  • Report ID: 5166340 •
  • Format: PDF
TNF Inhibitors: An insight

The TNF inhibitors pipeline analysis report includes ongoing clinical and non-clinical trends in the global TNF inhibitors market. The anti-TNF drugs are among the top 10 global blockbuster drugs and have dominated the global pharmaceutical market landscape for many years. The report includes classification of the pipeline by type of molecules such monoclonal antibody, polyclonal antibody, recombinant fusion protein, and a small molecule.

Around 45% of TNF inhibitors in pipeline are being evaluated for the treatment of RA. According to the Centers for Disease Control and Prevention (CDC), around 78 million (26%) US adults aged 18 years or older are projected to have doctor-diagnosed arthritis by 2040.

Covered in this report
The report covers the present scenario and the growth prospects of the TNF inhibitors. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

Technavio’s TNF Inhibitors - A Pipeline Analysis Report, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects during the forecast period. The report also includes a discussion of the key companies operating in this market.

Major companies
• Pfizer
• Boehringer Ingelheim
• Novartis
• Amgen
• Mochida Pharmaceutical
• Hanall
• BioPharma

Key questions answered in this report
• How will the market evolve during the forecast period?
• What are the major parameters impacting the market?
• What are the key market trends?
• What are the challenges to market growth?
• Who are the key companies in this market space?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

We are very sorry, but an error occurred.
Please contact if the problem remains.